This mutation would be associated with the development of DLBCL and, furthermore, with a fraction of follicular lymphomas: following this alteration, activation of BCL6 and inhibition of TP53 are determined mechanisms that contribute to lymphomagenesis. This evidence concerns the gene BCL6 and follicular lymphoma.